Citations

Clear

1446 citation(s) found for "Howard, F".

Vascular burden and Alzheimer disease pathologic progression
Lo, Raymond Y. , Jagust, William J. , Weiner, Michael W. , Aisen, Paul , Petersen, Ronald , Trojanowki, John Q., Liu, Enchi , Montine, Tom, Petersen, Ronald, Gamst, Anthony, Thomas, Ronald G. , Walter, Sarah , Gessert, Devon, Sather, Tamie, Kornak, John , Felmlee, Joel P. , Schuff, Norbert, Alexander, Gene, DeCarli, Charles , Bandy, Dan, Foster, Norm, Reiman, Eric M. , Mathis, Chet, Cairns, Nigel J., Taylor‐Reinwald, Lisa, Shaw, Les, Korecka, Magdalena , Crawford, Karen , Neu, Scott, Foroud, Tatiana M., Potkin, Steven, Kachaturian, Zaven, Frank, Richard , Molchan, Susan, Quinn, Joseph, Lind, Betty, Dolen, Sara, Schneider, Lon S. , Pawluczyk, Sonia, Spann, Bryan M., Brewer, James, Vanderswag, Helen, Heidebrink, Judith L. , Johnson, Kris , Doody, Rachelle S., Villanueva‐Meyer, Javier , Chowdhury, Munir , Bell, Karen L. , Carroll, Maria , Leon, Sue, Mintun, Mark A., Schneider, Stacy, Marson, Daniel , Griffith, Randall, Clark, David, Grossman, Hillel, Mitsis, Effie, Romirowsky, Aliza, deToledo‐Morrell, Leyla, Duara, Ranjan , Varón, Daniel , Roberts, Peggy, Albert, Marilyn, Onyike, Chiadi, Kielb, Stephanie , Glodzik, Lidia , Santi, Susan De , Doraiswamy, P. Murali , Petrella, Jeffrey R. , Coleman, R. Edward, Arnold, Steven E. , Karlawish, Jason H., Smith, Charles D., Jicha, Gregory A. , Hardy, Peter , Oakley, MaryAnn, Simpson, Donna M., Goldstein, Bonnie S., Martin, Kim, Makino, Kelly M., Ismail, M. Saleem , Brand, Connie, Mulnard, Ruth A., Thai, Gaby , Mc-Adams-Ortiz, Catherine, Mathews, Dana, Quiceno, Mary , King, Richard, Weiner, Myron, Martin-Cook, Kristen, Devous, Michael D. , Cellar, Janet S., Anderson, Heather S., Swerdlow, Russell H. , Apostolova, Liana , Lu, Po H. , Bartzokis, George, Graff‐Radford, Neill R. , Parfitt, Francine, Farlow, Martin R. , Hake, Ann Marie , Matthews, Brandy R., Herring, Scott, Dyck, Christopher H. van , Carson, Richard E. , MacAvoy, Martha G., Chertkow, Howard , Bergman, Howard , Hosein, Chris, Black, Sandra, Stefanovic, Dr Bojana, Caldwell, Curtis, Hsiung, Ging‐Yuek Robin , Mudge, Benita, Assaly, Michele, Kertesz, Andrew, Rogers, John, Trost, Dick, Bernick, Charles , Munic, Donna, Mesulam, Marek-Marsel, Lipowski, Kristina, Wu, Chuang‐Kuo, Johnson, Nancy , Sadowsky, Carl, Villena, Teresa, Johnson, Kathleen, Reynolds, Brigid, Johnson, Keith A., Marshall, Gad A. , Frey, Meghan , Yesavage, Jerome A. , Taylor, Joy L. , Lane, Barton , Rosen, Allyson , Tinklenberg, Jared, Sabbagh, Marwan N. , Belden, Christine M. , Jacobson, Sandra A. , Kowall, Neil W. , Budson, Andrew E. , Johnson, Patricia Lynn, Wolday, Saba, Bwayo, Salome K., Lerner, Alan J. , Hudson, Leon, Ogrocki, Paula, Fletcher, Evan, Olichney, John , Kittur, Smita, Borrie, Michael, Lee, T‐Y, Bartha, Dr Rob, Asthana, Sanjay , Carlsson, Cynthia M., Preda, Adrian , Tariot, Pierre N. , Fleisher, Adam , Reeder, Stephanie, Bates, Vernice, Capote, Horacio, Rainka, Michelle, Kataki, Maria , Zimmerman, Earl A. , Celmins, Dzintra, Brown, Alice D., Blank, Karen, Anderson, Karen, Santulli, Robert B. , Schwartz, Eben S., Williamson, Jeff D. , Garg, Pradeep , Watkins, Franklin, Ott, Brian R. , Querfurth, Henry, Tremont, Geoffrey , Salloway, Stephen , Malloy, Paul, Correia, Stephen , Rosen, Howard J. , Mintzer, Jacobo , Longmire, Crystal Flynn, Spicer, Kenneth, Rachinsky, Irina, Rogers, John , Drost, Dick, Lee, Ting‐Yim , Jack, Clifford R. , Toga, Arthur W. , Beckett, Laurel , Green, Robert C. , Saykin, Andrew J. , Morris, John C. , Donohue, Michael , Harvey, Danielle , Dale, Anders M. , Bernstein, Matt A. , Fox, Nick C. , Thompson, Paul M. , Koeppe, Robert A. , Chen, Kewei , Mathis, Chet, Lee, Virginia M.‐Y. , Shen, Li , Snyder, Peter J. , Kaye, Jeffrey , Lord, Joanne L. , Stern, Yaakov , Honig, Lawrence S. , Ances, Beau M. , Shah, Raj C. , Duara, Ranjan , Rusinek, Henry , Leon, Mony J. de , Karlawish, Jason , Wolk, David A. , López, Oscar L. , Porsteinsson, Anton P. , Womack, Kyle , Diaz‐Arrastia, Ramon , Levey, Allan I. , Lah, James J. , Burns, Jeffrey M. , Silverman, Daniel H.S. , Johnson, Heather K. , Stefanovic, Bojana , Feldman, Howard , Kerwin, Diana , Martínez, Walter Fabián , Turner, Raymond Scott , Sperling, Reisa Anne , Killiany, Ronald , Norbash, Alexander , Obisesan, Thomas O. , Carmichael, Owen , Johnson, Sterling C. , Nguyen, Dana R. , Reeder, Stephanie, Scharre, Douglas W. , Pearlson, Godfrey D. , Sink, Kaycee M. , Miller, Bruce L. , Finger, Elizabeth C. , Preda, Adrian , Hsiung, Gink-Yuek , Jicha, Gregory A

Mayo Clinic

Neurology | September 13, 2012 | Volume: 79 | Issue: 13 | Pages: 1349-1355

10.1212/wnl.0b013e31826c1b9d | PMID 22972646 Get It

Mutations in BCKD-kinase Lead to a Potentially Treatable Form of Autism with Epilepsy
Novarino, Gaia , El-Fishawy, Paul, Kayserili, Hülya , Meguid, Nagwa A. , Scott, Eric , Schroth, Jana, Silhavy, Jennifer L., Kara, Majdi , Khalil, Rehab O., Ben‐Omran, Tawfeg , Ercan‐Sencicek, A. Gulhan , Hashish, Adel F. , Sanders, Stephan , Gupta, Abha R. , Hashem, Hebatalla S., Matern, Dietrich , Gabriel, Stacey , Sweetman, Larry, Rahimi, Yasmeen, Harris, Robert A. , State, Matthew W. , Gleeson, Joseph G. , Sanders, Stephan J

Mayo Clinic

Science | September 6, 2012 | Volume: 338 | Issue: 6105 | Pages: 394-397

10.1126/science.1224631 | PMID 22956686 Get It

A Fine Balance Intellectual and neurological disabilities can arise from diverse developmental aberrations. Novarino et al. (p. 394 , published online 6 September; see the Perspective by Beaudet ) have now determined the genetic basis for one such disorder for a small group of patients. Exome sequencing led to identification of mutations in a kinase BCKDK ( Branched Chain Ketoacid Dehydrogenase Kinase ) that regulates metabolism of branched-chain amino acids such as valine, leucine, and isoleucine. Mice with homozygous mutations in the BCKDK gene showed developmental and neurological abnormalities resembling those in certain mouse autism models. Analysis of transport mechanisms responsible for carrying amino acids across the blood-brain barrier revealed competition between the branched-chain amino acids and large neutral amino acids. Nutritional supplementation with extra branched-chain amino acids in the diet of mice carrying homozygous mutations in the BCKDK gene normalized their phenotype.
Dual recognition of phosphoserine and phosphotyrosine in histone variant H2A.X by DNA damage response protein MCPH1
Singh, Namit , Basnet, Harihar , Wiltshire, Timothy D. , Mohammad, Duaa H., Thompson, James R. , Héroux, A. , Botuyan, Maria Victoria , Mer, Georges , Yaffe, Michael B. , Couch, Fergus J. , Rosenfeld, Michael G.

Mayo Clinic

Proceedings of the National Academy of Sciences | August 21, 2012 | Volume: 109 | Issue: 36 | Pages: 14381-14386

10.1073/pnas.1212366109 | PMID 22908299 Get It

Tyr142, the C-terminal amino acid of histone variant H2A.X is phosphorylated by WSTF (Williams-Beuren syndrome transcription factor), a component of the WICH complex (WSTF-ISWI chromatin-remodeling complex), under basal conditions in the cell. In response to DNA double-strand breaks (DSBs), H2A.X is instantaneously phosphorylated at Ser139 by the kinases ATM and ATR and is progressively dephosphorylated at Tyr142 by the Eya1 and Eya3 tyrosine phosphatases, resulting in a temporal switch from a postulated diphosphorylated (pSer139, pTyr142) to monophosphorylated (pSer139) H2A.X state. How mediator proteins interpret these two signals remains a question of fundamental interest. We provide structural, biochemical, and cellular evidence that Microcephalin (MCPH1), an early DNA damage response protein, can read both modifications via its tandem BRCA1 C-terminal (BRCT) domains, thereby emerging as a versatile sensor of H2A.X phosphorylation marks. We show that MCPH1 recruitment to sites of DNA damage is linked to both states of H2A.X.
Abstract 5562: Utility of circulating biomarkers as outcome predictors in metastatic colorectal cancer and recurrent glioblastoma multiforme patients treated with bevacizumab/sorafenib
Lafky, Jacqueline M., Anderson, S. Keith , Morlan, Bruce W., Nelson, Garth D. , Carrero, Xiomara W., Kumar, Shaji , Reynolds, John T., Stella, Philip J., Dakhil, Shaker R. , Loui, William S., Flynn, Patrick J. , Gross, Howard M., Jaeckle, Kurt A. , Buckner, Jan C. , Grothey, Axel, Alberts, Steven R. , Galanis, Evanthia

Mayo Clinic

Cancer Research | August 13, 2012 | Volume: 72 | Issue: 8_Supplement | Pages: 5562-5562

10.1158/1538-7445.am2012-5562 Get It

Abstract Purpose: Surrogate biomarkers are lacking for predicting or monitoring response to anti-angiogenesis therapies. We investigated whether circulating biomarkers (CBMs) of angiogenesis (i.e., bFGF, SDF-1α, HGF, sKIT, Ang-2, and PlGF) correlated with treatment efficacy in a pooled analysis of metastatic colorectal cancer (mCRC) and recurrent glioblastoma multiforme (rGBM) patients (pts) treated with bevacizumab/sorafenib (BEV/SOR). Experimental procedures: Peripheral blood samples were obtained for CBM analyses from pts enrolled in the North Central Cancer Treatment Group (NCCTG) phase II studies N054C (mCRC, n=75, Grothey, ASCO 2010) and N0776 (rGBM, n=54, Galanis, ASCO 2010). Blood collection time points were: baseline (BL), cycle 1 day 3 (C1D3), prior to treatment cycles 2, 3, 5, 7, 9, 11, 13, and after the pt went off study. Plasma CBM levels were determined by commercially-available ELISAs (R&D Systems) and performed according to manufacturer's instructions. For each CBM, a linear regression model that adjusted for study was used to evaluate the correlation with either progression-free survival (PFS) success/failure or progression within 14 days of the last blood draw for the following measures: absolute BL levels, log2 BL levels; C1D3 log2-fold change (FC) from BL, prior to cycle 2 log2-FC from BL, last draw log2-FC from BL, and last draw log2-FC from prior draw. Results summary: There appears to be no significant difference in the PFS or overall survival (OS) between the pts on these two studies; therefore, we pooled the patients from both studies for a combined analyses. We found no difference in absolute or log2 levels for any of the CBMs during the course of BEV/SOR treatment. In these pooled analyses, we found increased absolute and increased log2 BL SDF-1α levels were significantly correlated with PFS success (p=0.023 and p=0.02, respectively). After correcting for multiple comparisons (method of Benjamini & Hochberg) the p-values <0.05 had a false-discovery-rate of 41.4%. None of the other CBM measures were significantly correlated with either PFS success/failure or progression within 14 days of the last blood draw (all p>0.10). Conclusions: This study provides preliminary evidence that SDF-1α may be a useful CBM for determining treatment efficacy in these pts treated with BEV/SOR. Further prospective validation of SDF-1α for predicting pt progression with this treatment combination in advanced disease (e.g., mCRC and rGBM) appears warranted. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5562. doi:1538-7445.AM2012-5562
Abstract 2628: Genome-wide sequencing identifies ATM as a pancreatic cancer susceptibility gene
Yu, Jun , Kopelovich, Levy, Petersen, Gloria M. , Bondy, Melissa L. , Gallinger, Steven , Schwartz, Ann G. , Axilbund, Jennifer E., Schulick, Richard, Ali, Syed Z. , Eshleman, James R. , Vogelstein, Bert , Papadopoulous, Nikolas, Hruban, Ralph H. , Kinzler, Kenneth W. , Roberts, Nicholas J. , Jiao, Yuchen , Syngal, Sapna , Coté, Michele L. , Velculescu, Victor E. , Goggins, Michael , Klein, Alison P.

Mayo Clinic

Cancer Research | August 9, 2012 | Volume: 72 | Issue: 8_Supplement | Pages: 2628-2628

10.1158/1538-7445.am2012-2628 Get It

Abstract Pancreatic ductal adenocarcinoma (PDA) affects over 44,000 people in the United States every year and carries a dismal prognosis, with a 5-year survival rate of just 5%. A subset of these patients (5-10%) report a familial history of the disease. The genetic etiology in these familial cases is poorly defined, with known susceptibility genes, such as: BRCA2, PALB2, CDKN2A, BRCA1, PRSS1 and STK11, accounting for only 10-15% of familial pancreatic cancer. In an effort to identify previously unappreciated pancreatic cancer susceptibility genes, we used next generation sequencing technology to evaluate the whole genome and whole exome sequences of 16 (6 families) and 22 individuals (10 families) respectively. All of these families enrolled into one of the familial pancreatic cancer registries participating in the Pancreatic Cancer Genetic Epidemiology (PacGene) Consortium, all had at least three members with PDA, and DNA was available from at least two affected members in each kindred. Using this approach, we identified heterozygous, inactivating, ATM mutations in two kindreds with familial pancreatic cancer (c.8266A>AT; p.K2756X and c.170G>GA; p.W57X). These mutations were previously reported as disease causing variants in patients with ataxia-telangiectasia, an autosomal recessive condition resulting from bi-allelic deleterious mutations of ATM. Interestingly, heterozygotes of deleterious ATM mutations have an increased risk of breast cancer. However, there have been no previous reports of deleterious ATM mutations in the germline of familial PDA patients. In our study, mutations segregated with disease in both kindreds and tumor analysis demonstrated Loss of heterozygosity (LOH) of the wild-type allele. Sequence analysis of the entire ATM gene in an additional 166 familial pancreatic cancer probands indentified four additional patients with deleterious mutations in the ATM gene (c.3214G>GT; p.E1072X, c.6095G>GA; p.R2032K, IVS41-1G>GT and c.3801delG), while no deleterious mutations were identified in 190 spouse controls (p=0.046). When considering only the mostly severely affected families, those with three or more pancreatic cancer cases, four deleterious mutations were found in 87 families (P=0.009). These results indicate that ATM mutations play an important role in familial pancreatic cancer predisposition and have significant implications in the management of affected individuals and the risk assessment of family members. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2628. doi:1538-7445.AM2012-2628
The Microculture-Kinetic (MiCK) Assay: The Role of a Drug-Induced Apoptosis Assay in Drug Development and Clinical Care
Prendergast, Franklyn G., Fleisher, Martin, Salom, Emery, Strickland, Stephen A. , Raptis, Anastasios, Hallquist, Allan, Perrée, Mathieu, Rajurkar, Swapnil, Karimi, Misagh, Rogers, Karl, Davidson, Dirk, Willis, C. , Peñalver, Manuel, Homesley, Howard D., Burrell, Matthew O., Garrett, Audrey P., Rutledge, James, Chernick, Michael R., Presant, Cary A. , Bosserman, Linda D. , Herbst, Roy S. , Strickland, Stephen Anthony

Mayo Clinic

Cancer Research | August 4, 2012 | Volume: 72 | Issue: 16 | Pages: 3901-3905

10.1158/0008-5472.can-12-0681 | PMID 22865459 Get It

Abstract A drug-induced apoptosis assay, termed the microculture-kinetic (MiCK) assay, has been developed. Blinded clinical trials have shown higher response rates and longer survival in groups of patients with acute myelocytic leukemia and epithelial ovarian cancer who have been treated with drugs that show high apoptosis in the MiCK assay. Unblinded clinical trials in multiple tumor types have shown that the assay will be used frequently by clinicians to determine treatment, and when used, results in higher response rates, longer times to relapse, and longer survivals. Model economic analyses suggest possible cost savings in clinical use based on increased generic drug use and single-agent substitution for combination therapies. Two initial studies with drugs in development are promising. The assay may help reduce costs and speed time to drug approval. Correlative studies with molecular biomarkers are planned. This assay may have a role both in personalized clinical therapy and in more efficient drug development. Cancer Res; 72(16); 3901–5. ©2012 AACR.
Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseases
Blitterswijk, Marka van , Vlam, Lotte, Doormaal, Perry T.C. van , Seelen, Meinie, Medic, Jelena, Dooijes, Dennis , Visser, Marianne de, Kooi, Anneke J. van der , Raaphorst, Joost , Schelhaas, Helenius J. , Pol, W. Ludo van der , Veldink, Jan H. , Berg, Leonard H. van den , Aisen, Paul , Petersen, Ronald C., Clifford, R. Jack, Jagust, William, Trojanowki, John Q., Liu, Enchi , Montine, Tom, Gamst, Anthony, Thomas, Ronald G. , Walter, Sarah , Gessert, Devon, Sather, Tamie, Harvey, Danielle, Kornak, John , Felmlee, Joel P. , Schuff, Norbert, Alexander, Gene, DeCarli, Charles, Bandy, Dan, Foster, Norm, Reiman, Eric M., Mathis, Chet, Cairns, Nigel J. , Taylor‐Reinwald, Lisa, Shaw, Les, Korecka, Magdalena , Crawford, Karen , Neu, Scott, Foroud, Tatiana, Potkin, Steven, Kachaturian, Zaven, Frank, R.T., Dolen, Sara, Schneider, Lon S. , Pawluczyk, Sonia, Spann, Bryan M., Brewer, James B., Vanderswag, Helen, Heidebrink, Judith L. , Petersen, Ronald C. , Johnson, Kris , Doody, Rachelle S., Villanueva‐Meyer, Javier , Chowdhury, Munir , Honig, Lawrence S., Bell, Karen L. , Mintun, Mark A., Schneider, Stacy, Marson, Daniel , Griffith, Randall, Grossman, Hillel, Mitsis, Effie, Romirowsky, Aliza, deToledo‐Morrell, Leyla, Duara, Ranjan , Varón, Daniel , Roberts, Peggy, Albert, Marilyn , Onyike, Chiadi U. , Kielb, Stephanie , Glodzik, Lidia , Doraiswamy, P. Murali , Petrella, Jeffrey R. , Arnold, Steven E. , Karlawish, Jason H., Smith, Charles D., Hardy, P. , Lopez, Oscar L., Oakley, MaryAnn, Simpson, Donna M., Ismail, M. Saleem, Brand, Connie, Mulnard, Ruth A., Thai, Gaby , Mc-Adams-Ortiz, Catherine, Martin-Cook, Kristen, Devous, Michael D. , Cellar, Janet S., Anderson, Heather S., Swerdlow, Russell H. , Bartzokis, George, Lu, Po H. , Apostolova, Liana G. , Graff‐Radford, Neill R. , Parfitt, Francine, Farlow, Martin, Herring, Scott, Hake, Ann Marie , Dyck, Christopher H. van , Carson, Richard E. , MacAvoy, Martha G., Chertkow, Howard, Bergman, Howard , Hosein, Chris, Black, Sandra, Caldwell, Curtis, Assaly, Michele, Kertesz, Andrew , Rogers, John, Trost, Dick, Bernick, Charles , Munic, Donna, Wu, Chuang‐Kuo, Johnson, Nancy E., Mesulam, Marsel, Sadowsky, Carl, Villena, Teresa, Johnson, Kathleen A., Reynolds, Brigid, Sperling, Reisa A., Frey, Meghan , Johnson, Keith A. , Rosen, Allyson , Tinklenberg, Jared, Belden, Christine M. , Jacobson, Sandra A. , Wolday, Saba, Bwayo, Salome K., Lerner, Alan J. , Hudson, Leon, Ogrocki, Paula, Kittur, Smita, Borrie, Michael, Lee, T‐Y, Bartha, Robert , Asthana, Sanjay , Tariot, Pierre N. , Fleisher, Adam , Reeder, Stephanie, Bates, Vernice, Capote, Horacio, Rainka, Michelle, Hendin, Barry , Kataki, Maria , Zimmerman, Earl A. , Celmins, Dzintra, Brown, Alice D., Blank, Karen, Anderson, Karen, Santulli, Robert B. , Schwartz, Eben S., Williamson, Jeff D. , Watkins, Franklin, Ott, Brian R. , Querfurth, Henry, Tremont, Geoffrey , Salloway, Stephen , Malloy, Paul, Correia, Stephen , Rosen, Howard J., Mintzer, Jacobo , Longmire, Crystal Flynn, Spicer, Kenneth, Kwon, Sun-Uck, Kim, Joon‐Tae , Cho, Ki-Hyun , Ko, Y.J., Lee, Soo Joo , Cha, Jae-Kwan, Shin, Dong-Jin, Jang, Hyuk Jae, Choi, Nack‐Cheon , Hong, Seok-Chang, Rha, Joung-Ho, Kim, Eung‐Gyu , Choi, Jay Chol , Shin, Won Chul , HyukHeo, Sung, Chung, Kyung Cheon, Lee, Jun Hong , Bae, Hee‐Joon , Lee, Tae‐Kyeong , Jeong, Dushin, Lee, Jun , Ashwal, Steve, deVeber, Gabrielle , Ichord, Rebecca , Kirkham, Fenella J. , Lynch, John K., O’Callaghan, Finbar , Pavlakis, Steve, Sébire, Guillaume , Willan, Andrew R. , Dlamini, Noma, Nowak-Göttl, Ulrike, Düring, Christine, Plumb, Patricia , Journeycake, Janna M., Bruinhorst, Katrina van de, Gossett, Daniel R., Chavez, Marta Isabel Hernandez, Barnes, Chris , Furmedge, Janine, Gordon, Anne , Benedict, Susan, Bale, James F. , Nielson, Denise, Kabbouche, Marielle A., Karti, Pooja, Phillips, Tonya, Rizkallah, Élie, Zamel, Khaled, Wiznitzer, Max , Lidsky, Karen , Bernard, Timothy J. , Goldenberg, Neil A. , Booth, Frances, Nash, Monica, Beslow, Lauren A. , Carpenter, Jessica L. , Weinstein, Steven L., Li, Kan , Smith, Robin, Maytal, Joseph, Sy-Kho, Rosemarie, Yager, Jerome Y. , Massicotte, Patti, McClure, Chalmer, Hukin, Juliet, Bucevska, Marija, Kent, Sheila, Riviello, James J. , Rivkin, Michael, Trenor, Cameron C. , Whelan, Harry T. , Goodman, Sharon, Levinson, Kim, Kolk, Anneli , Laugesaar, Rael , Talvik, Tiina, Imam, Hussain, Thomas, Terrence , Kirton, Adam , Ganesan, Vijeya , Saengpattrachai, Montri, Crosswell, Hal E., Mancuso, Ann, Yeh, E. Ann , Humpherys, Peter, Abraham, Lisa , Alveal, Lucila Andrade, Ortiz, Manuel Arriaza, Altuna, Diana, Maxit, Clarisa, González, Verónica , Alam, Muhammad Rafiqul , Buckley, David , Penney, Sharon, Grabowski, Eríc F. , Deray, Marcel J., Khatib, Zaid, Kosofsky, Barry E. , Leifer, Dana , Nass, Ruth, Wong, Virginia, Catsman, Coriene E. , El-Hakam, Lisa Michael, Cholette, Jill M., Narang, Shalu, Lerner, Norma B., Carpenter, Shannon L. , Bischoff, Kurt, Frei‐Jones, Melissa , Masur, David, Gallentine, William B., Rende, Elizabeth K., Provenzale, James, Voyvodic, James , Song, Allen W. , Conklin, Terrie, O’Hara, Kathryn, Seinfeld, Syndi, Conry, Joan A. , Ayala, Jennifer , Facchini, Ronda, Sigalova, Maryana, Hannigan, James, Mancini, Ann , Curran, John S. , Ahlm, Sarah, Renaldi, J., Umanzour, Diana K, Kim, Andrew, Hamidullah, Aaliyah, Litherland, Claire , Bonner, Melanie, Xu, Yuan , Water, Virginia Van de, Grasso, Susan, Culbert, James, Bush, Brian J., Chandrasekaran, Sreedevi, Davis, Lori L. , Rogers, Christiane, Sabo, Cynthia , Wang, Helen H. , Lee, Ting‐Yim , Rheenen, Wouter van , Huisman, Mark H. B. , Weiner, Michael D. , Toga, Arthur W. , Beckett, Laurel , Green, Robert C. , Saykin, Andrew J. , Morris, John C. , Donohue, Michael , Dale, Anders M. , Bernstein, Matt A. , Fox, Nick C. , Thompson, Paul M. , Koeppe, Robert A. , Reiman, Eric M. , Chen, Kewei , Mathis, Chet, Lee, Virginia M.‐Y. , Shen, Li , Snyder, Peter J. , Kaye, Jeffrey , Quinn, Joseph F. , Lord, Joanne L. , Stern, Yaakov , Honig, Lawrence S. , Clark, David , Grossman, Hillel, Shah, Raj C. , Duara, Ranjan , Rusinek, Henry , Leon, Mony J. de , Karlawish, Jason , Wolk, David A. , Jicha, Gregory A. , Lopez, Oscar L., Diaz‐Arrastia, Ramon , Levey, Allan I. , Lah, James J. , Burns, Jeffrey M. , Silverman, Daniel H.S. , Johnson, Heather K. , Farlow, Martin R. , Stefanovic, Bojana , Hsiung, Ging‐Yuek Robin , Feldman, Howard , Martínez, Walter Fabián , Turner, Raymond Scott , Sabbagh, Marwan Noel , Killiany, Ronald , Norbash, Alexander , Obisesan, Thomas O. , Fletcher, Evan M. , Carmichael, Owen , Johnson, Sterling C. , Carlsson, Cynthia M. , Potkin, Steven G. , Preda, Adrian , Nguyen, Dana R. , Scharre, Douglas W. , Pearlson, Godfrey D. , Sink, Kaycee M. , Miller, Bruce L. , Shin, Dong‐Ick , Kim, Yong‐Jae , Rha, Joung‐Ho , Hong, Keun‐Sik , Sohn, Sung‐Il , Park, Jong‐Ho , Park, Jong‐Moo , Park, Tai Hwan , Han, Moon‐Ku , Kwon, Hyung‐Min , Lee, Kyung‐Bok , Ashwal, Steven, Ferriero, Donna Marie , Fullerton, Heather J. , Lynch, John K., Sofronas, Marianne , Elbers, Jorina M. , Krümpel, Anne , Monagle, Paul , Mackay, Mark T. , Abdalla, Abdalla , Chadehumbe, Madeline , Friedman, Neil , Armstrong, Jennifer , Chang, Taeun , Sy-Kho, Rose Marrie, Björnson, Bruce , Hukin, Juliette , Amlie‐Lefond, Catherine , Fox, Christine K. , Golomb, Meredith R. , Heyer, Geoffrey L. , Tatishvili, Nana Nino , Jordan, Lori C. , Chan, Anthony K.C. , Kovacevic, Gordana S. , Epstein, Leon G. , Bagiella, Emilia , Hinton, Veronica J. , Voyvodic, James T., Glauser, Tracy A. , Weiss, Erica F , Kushner, David B. , BUSH, BRIAN J. , Noebels, Jeffrey L. , van Blitterswijk, Marka , Veldink, Jan H

Mayo Clinic

Neurology | July 27, 2012 | Volume: 79 | Issue: 9 | Pages: 878-882

10.1212/wnl.0b013e3182661d14 | PMID 22843265 Get It

P4‐155: Longitudinal gray and white matter changes in progranulin mutation carriers at risk for FTD: A VBM study
Jang, Jae‐Won , Sengdy, Pheth, Kee, Baik Seok , Rademakers, Rosa , Mackenzie, Ian R. , Youn, Young Chul , Jacova, Claudia , Feldman, Howard , Hsiung, Ging‐Yuek Robin

Mayo Clinic

Alzheimer's & Dementia | July 19, 2012 | Volume: 8 | Issue: 4S_Part_19 | Pages: No page available

10.1016/j.jalz.2012.05.1859 Get It

Abstract 4679: A multi-stage genome-wide association study on response to chemotherapy in ovarian cancer
Johnatty, Sharon E. , Beesley, Jonathan, Chen, Xiao Qing, Webb, Penny, Haber, Michelle , Goode, Ellen L. , Fazio, Anna de , MacGregor, Stuart , Lu, Yi , Chen, Xiao Qing, Fridley, Brooke L. , Webb, Penny, Gurney, Howard , Harnett, Paul R. , Chenevix‐Trench, Georgia , Haber, Michelle

Mayo Clinic

Cancer Research | June 27, 2012 | Volume: 71 | Issue: 8_Supplement | Pages: 4679-4679

10.1158/1538-7445.am2011-4679 Get It

Abstract We performed a multi-stage genome-wide association study (GWAS) for drug response in ovarian cancer. We selected 313 chemotherapy treated patients from the Australian Ovarian Cancer Study (AOCS). Patients were treated with paclitaxel/carboplatin and the trait of interest was Progression Free Survival (PFS). We maximized power for a fixed genotyping budget by genotyping individuals from the tails of the distribution: 94 with good survival and 94 with poor survival, taking into account extent of residual disease following surgery. Patients were genotyped on Illumina HumanOmni1-Quad arrays (1140419 loci).Two further cohorts with measures of PFS and whole genome data available; 134 ovarian patients from the Mayo clinic (genotyped on Illumina HumanHap 610 arrays, 620901 loci) and 68 patients from The Cancer Genome Atlas ovarian cancer set (genotyped on Illumina Human1M arrays, 1199187 loci) were meta-analyzed with the AOCS set (stage 1). We have imputed all the stage 1 samples with reference of the 1000 Genome data to allow more direct comparison of SNPs not common to all of the arrays used (up to 6 million SNPs with good imputation quality). Based on the chemotherapy treatment received by each patient, we assigned the patients into primary and secondary analysis, with primary analysis using a more strictly defined treatment subgroup. We followed up the stage 1 findings by genotyping 26 SNPs in more than 3,000 samples collected from 8 study sites of Ovarian Cancer Association Consortium (OCAC). These 26 SNPs were mainly genotyped SNPs, chosen from 23 distinct regions showing the strongest association with chemotherapy response from either primary or secondary analysis. 2 SNPs showed nominal significance in the replication sample (chr 12: rs1861932, chr 22: rs708444). We are currently genotyping more regions to seek replication of the initial findings. In summary, we sought to identify genes that underlie individual differences in chemoresistance. In the future, typing variations in these genes will be important for personalizing drug regimes for patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4679. doi:10.1158/1538-7445.AM2011-4679
Association of Prediabetes and Diabetes With Stroke Symptoms
Carson, April P. , Muntner, Paul , Kissela, Brett , Kleindorfer, Dawn , Howard, Virginia J. , Williams, Linda S. , Prineas, Ronald J. , Howard, George , Safford, Monika M. , Meschia, James F. , Carson, April P , Howard, Virginia J , Howard, George

Mayo Clinic

Diabetes Care | June 15, 2012 | Volume: 35 | Issue: 9 | Pages: 1845-1852

10.2337/dc11-2140 | PMID 22699292 Get It

OBJECTIVE Stroke symptoms among individuals reporting no physician diagnosis of stroke are associated with an increased risk of future stroke. Few studies have assessed whether individuals with diabetes or prediabetes, but no physician diagnosis of stroke, have an increased prevalence of stroke symptoms. RESEARCH DESIGN AND METHODS This study included 25,696 individuals aged ≥45 years from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study who reported no history of stroke or transient ischemic attack at baseline (2003–2007). Glucose measurements, medication use, and self-reported physician diagnosis were used to categorize participants into diabetes, prediabetes, or normal glycemia groups. The presence of six stroke symptoms was assessed using a validated questionnaire. RESULTS The prevalence of any stroke symptom was higher among participants with diabetes (22.7%) compared with those with prediabetes (15.6%) or normal glycemia (14.9%). In multivariable models, diabetes was associated with any stroke symptom (prevalence odds ratio [POR] 1.28 [95% CI 1.18–1.39]) and two or more stroke symptoms (1.26 [1.12–1.43]) compared with normal glycemia. In analyses of individual stroke symptoms, diabetes was associated with numbness (1.15 [1.03–1.29]), vision loss (1.52 [1.31–1.76]), half-vision loss (1.54 [1.30–1.84]), and lost ability to understand people (1.34 [1.12–1.61]) after multivariable adjustment. No association was present between prediabetes and stroke symptoms. CONCLUSIONS In this population-based study, almost one in four individuals with diabetes reported stroke symptoms, which suggests that screening for stroke symptoms in diabetes may be warranted.